Riptide Bioscience

Founded in 2012 and based in Vallejo, California, Riptide Bioscience is a private, preclinical-stage biotech focused on a platform of engineered Host Defense Peptides (HDPs). The company designs synthetic peptides with significantly enhanced efficacy over natural versions to address infection and dysregulated inflammation. Riptide has advanced its research through collaborations with academic institutions and non-dilutive funding from U.S. government agencies, positioning itself for potential pharmaceutical partnerships to develop its proprietary drug candidates.

Proprietary platform for engineering synthetic Host Defense Peptides (HDPs) with enhanced antimicrobial and immunomodulatory properties compared to natural versions.

Riptide competes in the crowded anti-infective space with large pharma and biotechs, and in immunology with entrenched biologic therapies. Its differentiation hinges on demonstrating superior efficacy or safety with its engineered HDPs compared to existing antibiotics and anti-inflammatory drugs.